Incretin hormone release stimulation

"Incretin hormone release stimulation" is not a specific molecular target but rather refers to the physiological process by which certain gut hormones—primarily glucagon-like peptide 1 (GLP‑1) and glucose-dependent insulinotropic polypeptide (GIP)—are secreted from intestinal cells in response to nutrient intake. These hormones act on pancreatic beta cells via their respective G protein-coupled receptors to enhance glucose-dependent insulin secretion and play additional roles in appetite regulation, gastric emptying, bone metabolism, and cardiovascular health[1][2][3][5]. The term does not denote a single molecule or receptor but instead describes an important regulatory mechanism relevant for metabolic diseases such as type 2 diabetes and obesity. Therapeutic agents such as GLP‑1 receptor agonists and DPP‑4 inhibitors exploit this pathway by either mimicking incretins or preventing their degradation; however, these drugs act on specific proteins within the pathway—not on "stimulation" per se.

Other names

Stimulation of incretin hormone releaseIncretin secretion stimulationGut hormone release stimulation (context-dependent)